49 results match your criteria: "Clinical Investigations Center[Affiliation]"
Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase.
Therapie
November 2024
Réseau de recherche en épidémiologie clinique et en santé publique/French Clinical Research Infrastructure Network (RECaP F-CRIN) Inserm network, 54500 Vandoeuvre-lès-Nancy, France; Sorbonne Université, INSERM, institut Pierre-Louis d'épidémiologie et de Santé publique, AP-HP, hôpital Pitié-Salpêtrière, département de Santé publique, centre de pharmacoépidémiologie (Cephepi), CIC-1901, 75000 Paris, France.
Article Synopsis
- The study analyzes the use of the French National Health Data System (SNDS), which provides healthcare data for nearly the entire population of France, focusing on the trends in pharmacoepidemiological research based on this data.
- A systematic review of articles from 2012 to 2018 revealed an upward trend in published studies, with the majority focusing on drug utilization, safety, and effectiveness, and a notable concentration on medications for the nervous and cardiovascular systems.
- The findings suggest that while the SNDS is increasingly valuable for drug safety research, there is a need for more studies involving specific populations such as children, pregnant women, and the elderly, who are usually not represented in clinical trials.
SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria.
Haematologica
January 2024
Clinical Investigations Center, Hôpital Saint-Louis, Paris.
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).
Leukemia
August 2023
Université Paris Cité, Clinical Investigations Center, Saint-Louis Hospital, APHP, Paris, France.
Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase.
Drug Saf
January 2023
EA7323 "Therapeutic Assessment, and Perinatal and Pediatric Pharmacology", Paris Cité University, Paris, France.
Introduction: While antipsychotic-induced weight gain has been widely described in adults, it has yet to be better characterized in children and adolescents.
Objective: The aim of this study was to assess antipsychotic-induced weight-gain reporting in children and adolescents as compared to adults, and according to the type of antipsychotic.
Methods: The study is an observational, case-non-case study using individual case safety reports from the WHO global pharmacovigilance database VigiBase from 1 January 2000 to 2 June 2021.
Fertility and pregnancy outcomes in women with nonclassic 21-hydroxylase deficiency.
Clin Endocrinol (Oxf)
March 2023
Department of Endocrinology and Reproductive Medicine and Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Référence des Pathologies Gynécologiques Rares, AP-HP, IE3M, Hôpital Pitié-Salpêtrière, Paris, France.
Introduction: Overall fertility and pregnancy outcomes in patients with nonclassic congenital adrenal hyperplasia (NCCAH) have been poorly studied. It has been suggested that hydrocortisone (HC) may decrease the time to conceive (TTC) and the rate of miscarriage in these patients.
Objectives: To describe fertility and pregnancy outcomes in a large cohort of NCCAH women.
Long-Read Sequencing Identifies Novel Pathogenic Intronic Variants in Gitelman Syndrome.
J Am Soc Nephrol
February 2023
Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
Article Synopsis
- - Gitelman syndrome is a rare genetic disorder linked to mutations in the SLC12A3 gene, leading to serious electrolyte imbalances, including low potassium and magnesium levels.
- - This study used long-read sequencing on DNA samples from suspected patients to identify a second pathogenic variant in cases where only one was previously found, significantly increasing the diagnostic yield.
- - The findings revealed that 67% of patients had a second variant, which often led to more severe symptoms, highlighting the importance of considering intronic variants and the potential need for updated genetic testing methods in diagnosing Gitelman syndrome.
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
JAMA
September 2022
Rheumatology Department, Brest University Hospital, Brest, France.
Article Synopsis
- This study investigated the effectiveness of tocilizumab, an IL-6 antagonist, for treating glucocorticoid-dependent polymyalgia rheumatica, a condition with limited treatment options.
- Conducted as a double-blind, placebo-controlled trial, 101 patients participated over roughly three years, comparing the effects of tocilizumab and placebo alongside a standardized reduction of prednisone.
- Results showed that 67.3% of participants receiving tocilizumab met the primary efficacy goal, compared to 31.4% in the placebo group, indicating a significant difference in disease activity reduction.
Background: The three main cardiac amyloidosis (CA) types have different progression and prognosis. Little is known about the mode of death (MOD) which is commonly attributed to cardiovascular causes in CA. Improving MOD's knowledge could allow to adapt patient care.
View Article and Find Full Text PDFThe challenge of targets and drug discovery using large-scale screening approaches in onco-hematology.
Therapie
April 2022
Inserm CIC1427, Clinical Investigations Center, hôpital Saint-Louis, université de Paris, AP-HP, 75010 Paris, France; Inserm UMR 1131, Saint-Louis Research Institute, 75010 Paris, France. Electronic address:
Target identification and drug discovery roads have been widely improved over the past decades in onco-hematology. In this review, we summarize recent improvements in the use of physio-pathologically relevant models and innovative screening approaches to accelerate efficient drug development. Using acute myeloid leukemia as an example, we also discuss the main encountered pitfalls and propose alternative roads to improve the drug discovery journey in onco-hematology.
View Article and Find Full Text PDFThe Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition.
Clin Pharmacokinet
March 2022
Université de Tours, EA 4245 T2I, Tours, France.
Background And Objectives: Rituximab is an anti-CD20 monoclonal antibody approved in several diseases, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). The influence of underlying disease on rituximab pharmacokinetics has never been investigated for several cancer and non-cancer diseases simultaneously. This study aimed at assessing this influence using an integrated semi-mechanistic model accounting for target-mediated elimination of rituximab.
View Article and Find Full Text PDFThe Closed-Loop System Improved the Control of a Pregnant Patient with Type 1 Diabetes Mellitus.
Case Rep Endocrinol
September 2021
Fundación Clínica Valle del Lili, Clinical Investigations Center, Cali, Colombia.
Objective: Closed-loop insulin systems represent a technological advance in diabetes management but have rarely been studied in pregnancy. We report a case of a patient with type 1 diabetes mellitus who was previously a user of the Paradigm VEO pump and then migrated to Medtronic 670G. .
View Article and Find Full Text PDFFrailty screening in older patients with cancer in French Guiana: The limits of the G8 tool.
J Geriatr Oncol
March 2022
Oncology Unit, General Hospital, Saint-Laurent du Maroni, French Guiana; Claude-Bernard Lyon-1 University, Lyon, France. Electronic address:
Impact of Sex in the Efficacy of Perioperative Desensitization Procedures in Heart Transplantation: A Retrospective Cohort Study.
Front Immunol
September 2021
Sorbonne Université, service d'hémobiologie, AP.HP.6 Pitie-Salpetriere, Paris, France.
Background: Sensitized patients, i.e. recipients with preformed donor-specific HLA antibodies (pfDSA), are at high-risk of developing antibody-mediated rejections (AMR) and dying after heart transplantation (HTx).
View Article and Find Full Text PDFCOVID-19 vaccines and myocarditis.
Arch Cardiovasc Dis
August 2021
Sorbonne Université, Clinical Investigations Center Paris-Est, Hôpital Universitaire Pitié-Salpêtrière, AP-HP, INSERM, 75013 Paris, France.
Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study.
Cancers (Basel)
May 2021
Université de Paris, AP-HP, Dermatology Department, INSERM U976, Saint Louis Hospital, 75010 Paris, France.
Article Synopsis
- This study examined the clinical progression and treatment factors of classic/endemic Kaposi's Sarcoma (KS) by analyzing 160 patients diagnosed between 1990 and 2013.
- It found that 41.2% of these patients required systemic treatment (ST), with key risk factors for ST initiation including long time to diagnosis, type of KS, and lesion characteristics.
- Additionally, there was no significant difference in efficacy between treatment types, suggesting treatment decisions can be made based on the patient's overall health instead of specific medication effectiveness.
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.
Leukemia
September 2021
Université de Paris, Department of Hematology, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review.
Front Pharmacol
February 2021
Sorbonne Université, Clinical Investigations Center Paris-Est, AP.HP.6 Pitie-Salpetriere University Hospital, INSERM, Paris, France.
In patients with allogenic hematopoietic stem cell transplantation (allo-HSCT), immune-checkpoint inhibitors (ICI) are used to treat malignancy recurrence. However, ICI are also associated with graft vs. host disease (GVHD).
View Article and Find Full Text PDFPersistent Lymphocytopenia Does Not Increase Nosocomial Infection Risk in the ICU.
Am J Respir Crit Care Med
April 2021
University Medical Center Utrecht, Utrecht the Netherlands.
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.
Pharmaceuticals (Basel)
October 2020
Department of Internal Medicine, Robert Ballanger Hospital, 93600 Aulnay-Sous-Bois, France.
Article Synopsis
- Tocilizumab, an anti-interleukin-6 receptor treatment, showed potential benefits for severe COVID-19 pneumonia when given timely as a single 400 mg dose.
- In a study of 246 patients, those treated with tocilizumab had significantly better outcomes compared to those who did not receive the medication, with a lower rate of mortality and ventilatory support needed.
- The results indicated that tocilizumab could improve survival without the need for mechanical ventilation, making it a promising option for severe COVID-19 patients.
Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19.
Kidney Int Rep
October 2020
Assistance Publique-Hôpitaux de Paris Centre, Cochin University Hospital, Intensive Care Medicine Department, Paris, France.
'Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study'.
Epidemiol Psychiatr Sci
April 2020
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy.
Aims: Prevalence of the use of antipsychotics (APs) in the paediatric population is globally increasing. The aim of this study was to describe multinational trends and patterns in AP use in children and adolescents in Europe.
Methods: This was a dynamic retrospective cohort study comprising all children and adolescents (⩽18 years of age).
Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report.
Ann Hematol
April 2020
Hematology and transplantation unit, Saint Louis Hospital, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
Use of Negative Pressure Wound Therapy in Surgical Site Infection During Pregnancy: A Case Study.
J Wound Ostomy Continence Nurs
March 2020
María Fernanda Escobar-Vidarte, MD, MSc, Department of Gynecology and Obstetrics, Fundación Clínica Valle Del Lili, Cali, Colombia. Adriana Messa, MD, Department of Gynecology and Obstetrics, Fundación Clínica Valle Del Lili, Cali, Colombia. Albaro Jose Nieto, MD, Department of Gynecology and Obstetrics, Fundación Clínica Valle Del Lili, Cali, Colombia. Maria Paula Echavarría, MD, Department of Gynecology and Obstetrics, Fundación Clínica Valle Del Lili, Cali, Colombia. Javier Andres Carvajal, MD, Department of Gynecology and Obstetrics, Fundación Clínica Valle Del Lili, Cali, Colombia. Paula Andrea Fernández, MD, Clinical Investigations Center, Fundación Clinica Valle del Lili, Cali, Colombia.
Background: Surgical site infections (SSIs) are a known cause of morbidity and mortality; however, evidence related to management of SSIs during pregnancy is sparse.
Case: A 26-year-old female patient with an adnexal cystic lesion underwent laparotomy at 19 weeks of pregnancy. She experienced a late SSI 10 days after initial surgery, necessitating surgical debridement.
Resistance to Insulin in Patients with Gitelman Syndrome and a Subtle Intermediate Phenotype in Heterozygous Carriers: A Cross-Sectional Study.
J Am Soc Nephrol
August 2019
Department of Genetics,
Background: Gitelman syndrome is a salt-losing tubulopathy caused by mutations in the gene, which encodes the thiazide-sensitive sodium-chloride cotransporter. Previous studies suggested an intermediate phenotype for heterozygous carriers.
Methods: To evaluate the phenotype of heterozygous carriers of pathogenic mutations, we performed a cross-sectional study of patients with Gitelman syndrome, heterozygous carriers, and healthy noncarriers.
A proposal for a useful algorithm to diagnose small hepatocellular carcinoma on MRI.
Eur J Gastroenterol Hepatol
January 2020
Radiology Department, University Hospital of Angers.
Objective: To assess MRI features for the diagnosis of small hepatocellular carcinomas (HCCs) and especially for nodules not showing both of the typical hallmarks.
Patients And Methods: Three hundred and sixty-four cirrhotic patients underwent liver MRI for 10-30 mm nodules suggestive of HCC. The diagnostic performances of MRI features [T1, T2; diffusion-weighted (DW) imaging signal, enhancement, capsule, fat content] were tested, both individually and in association with both typical hallmarks and as substitutions for one hallmark.